Medpace Holdings Inc (NASDAQ:MEDP) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $74.67.
MEDP has been the subject of several analyst reports. ValuEngine downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd.
In other news, CFO Jesse J. Geiger sold 14,400 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $82.00, for a total transaction of $1,180,800.00. Following the completion of the sale, the chief financial officer now owns 16,948 shares in the company, valued at $1,389,736. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 24.20% of the company’s stock.
Shares of NASDAQ:MEDP opened at $90.95 on Wednesday. Medpace has a 1-year low of $50.14 and a 1-year high of $92.07. The firm has a market capitalization of $3.26 billion, a PE ratio of 35.12, a PEG ratio of 2.08 and a beta of 1.50. The business’s 50 day moving average is $82.25 and its 200-day moving average is $77.25. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.07.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.71 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.71. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The company had revenue of $216.20 million for the quarter, compared to analyst estimates of $217.14 million. During the same quarter last year, the firm earned $0.67 EPS. Medpace’s revenue for the quarter was up 20.6% compared to the same quarter last year. On average, sell-side analysts predict that Medpace will post 2.92 EPS for the current year.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.